To determine whether combined therapy with the lipid lowering agents colestipol
hydrochloride plus niacin would produce significant change in coronary, carotid, and femoral
artery atherosclerosis and coronary bypass graft lesions as determined by angiography. Also,
to determine possible correlations between lesion changes and plasma lipid and lipoprotein
cholesterol levels and to explore interrelationships of atherosclerosis change in femoral,
coronary, and carotid arteries.
The purpose of this study is to determine whether significant alterations in serum
lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis
progression or even induce regression.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.